Regn2810: Clinical Trials

31 trials of Regn2810, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

9 recruiting, 7 completed, 6 active not recruiting, 5 terminated. 31 Phase 1, 12 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 131Recruiting 9, Completed 7, Active not recruiting 6, Terminated 5, Not yet recruiting 2, Withdrawn 2
Phase 212Recruiting 5, Active not recruiting 2, Terminated 2, Completed 1, Not yet recruiting 1, Withdrawn 1

Follow Regn2810: new trials by email Literature Review of Regn2810 trials Research Report on Regn2810

Trials (filtered) newest first · largest first

All 31 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Testing the Combination of Anti-cancer Drugs Actimab-A and Cemiplimab (REGN2810) to Improve Outcomes for Patients With Recurrent Glioblastoma
Actinium Ac 225 Lintuzumab, Biospecimen Collection, Cemiplimab - Recurrent Glioblastoma, IDH-Wildtype, Recurrent Gliosarcoma
Phase 1Not yet recruitingNational Cancer Institute (NCI)302026-12-042026-06-12
A Safety and Efficacy Study of Combined Fianlimab + Cemiplimab in Children and Young Adults With Recurrent or Progressive High-Grade Glioma or Posterior Fossa-A Ependymoma
Cemiplimab, Cemiplimab+Fianlimab Fixed Dose Combination (FDC) - High-Grade Glioma (HGG), Posterior Fossa-A Ependymoma
Phase 1 / Phase 2Not yet recruitingRegeneron Pharmaceuticals1202026-08-312026-05-05
Testing the Effectiveness of the Anti-cancer Drug Pidnarulex (CX-5461), in Combination With Another Anti-cancer Drug Cemiplimab (REGN2810), in Treating Refractory Microsatellite Stable Colorectal Cancer
Biopsy Procedure, Biospecimen Collection, Cemiplimab - Metastatic Colorectal Adenocarcinoma, Refractory Colorectal Adenocarcinoma
Phase 1 / Phase 2RecruitingNational Cancer Institute (NCI)862026-08-102026-09-09
REGN15505 (PSMAx4-1BB) Alone or in Combination With Cemiplimab or REGN4336 (PSMAxCD3) in Adult Patients With Metastatic Castration-Resistant Prostate Cancer and Clear Cell Renal Cell Carcinoma
REGN15505, REGN15505+Cemiplimab, REGN15505+REGN4336 - Metastatic Castration-Resistant Prostate Cancer (mCRPC), Clear Cell Renal Cell Carcinoma (ccRCC)
Phase 1 / Phase 2RecruitingRegeneron Pharmaceuticals2652026-07-202026-09-28
A Study to Learn if 27T51, a Mucin-16 (MUC16) Protein Targeting Immune Cell Therapy, Administered Alone or in Combination is Safe and How Well it Works for Adult Participants With Recurrent or Treatment Resistant Ovarian Cancers
27T51, Cemiplimab, Bevacizumab - Epithelial Ovarian Cancer, Primary Peritoneal Carcinoma
Phase 1RecruitingRegeneron Pharmaceuticals902024-08-062026-02-03
Intravenous Vesicular Stomatitis Virus in Patients With Peripheral T-cell Lymphoma
Biopsy, Biospecimen Collection, Bone Marrow Biopsy - Peripheral T Cell Lymphoma, Relapsed Peripheral T-Cell Lymphoma
Phase 1RecruitingMayo Clinic212024-01-052026-07-01
Safety and Immunotherapeutic Activity of Cemiplimab in Participants With HBV on Suppressive Antiviral Therapy
Cemiplimab - Hepatitis B Virus
Phase 1 / Phase 2WithdrawnNational Institute of Allergy and Infectious Diseases (NIAID)2024-01-012023-09-07
A Study of ImmunoPet Imaging Using 89Zr-DFO-REGN5054 in Adult Participants With Solid Cancers Treated With Cemiplimab
89Zr˗DFO˗REGN5054, cemiplimab - Advanced Solid Tumor, Metastatic Solid Tumor
Phase 1Active not recruitingRegeneron Pharmaceuticals222023-02-072026-10-20
A Study to Examine the Effects of Novel Therapy Linvoseltamab in Combination With Other Cancer Treatments for Adult Participants With Multiple Myeloma That is Resistant to Current Standard of Care Treatments
Linvoseltamab, Daratumumab, Carfilzomib - Multiple Myeloma
Phase 1RecruitingRegeneron Pharmaceuticals3172022-08-172026-11-05
Glycan Mediated Immune Regulation With a Bi-Sialidase Fusion Protein (GLIMMER-01)
E-602, Cemiplimab - Oncology, Melanoma
Phase 1 / Phase 2CompletedPalleon Pharmaceuticals, Inc.692022-02-112025-08-20
SAR439459 and Cemiplimab for the Treatment of Advanced or Unresectable Solid Tumors, Strategic Alliance, TACTIC TRIAL
Anti-TGF-beta Monoclonal Antibody SAR-439459, Cemiplimab - Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm
Phase 1TerminatedM.D. Anderson Cancer Center32021-02-092023-08-14
A Trial to Find Out How Safe REGN7075 is and How Well it Works in Combination With Cemiplimab for Adult Participants With Advanced Cancers
REGN7075, Cemiplimab, Platinum-based doublet chemotherapy - Advanced Solid Tumors
Phase 1 / Phase 2Active not recruitingRegeneron Pharmaceuticals5482020-12-212026-07-02
A Study to Find Out How Safe REGN5668 is and How Well it Works In Adult Women When Given With Either Cemiplimab, or Cemiplimab + Fianlimab, or Ubamatamab
REGN5668, Cemiplimab, Ubamatamab - Ovarian Cancer, Fallopian Tube Cancer
Phase 1 / Phase 2RecruitingRegeneron Pharmaceuticals6122020-12-082026-09-24
Study of REGN6569 and Cemiplimab in Adult Patients With Advanced Solid Tumor Malignancies
REGN6569, Cemiplimab - Squamous Cell Carcinoma of Head and Neck
Phase 1TerminatedRegeneron Pharmaceuticals382020-10-052025-02-24
Short-term Fasting Prior to PD-1/PD-L1 Inhibitor Therapy for of Advanced or Metastatic Skin Malignancy
Atezolizumab, Avelumab, Cemiplimab - Advanced Malignant Skin Neoplasm, Metastatic Malignant Skin Neoplasm
Phase 1Active not recruitingUniversity of Southern California102020-08-122026-09-21
Cemiplimab Before and After Surgery for the Treatment of High Risk Cutaneous Squamous Cell Cancer
Cemiplimab, Radiation Therapy, Therapeutic Conventional Surgery - Metastatic Skin Squamous Cell Carcinoma, Recurrent Skin Squamous Cell Carcinoma
Phase 1Active not recruitingEmory University142020-05-152026-09-14
Safety and Immunotherapeutic Activity of an Anti-PD-1 Antibody (Cemiplimab) in Participants With HIV-1 on Suppressive cART
Cemiplimab, Placebo - HIV Infections
Phase 1 / Phase 2TerminatedNational Institute of Allergy and Infectious Diseases (NIAID)52019-08-132022-03-02
A Trial to Find Out if REGN5678 (Nezastomig) is Safe and How Well it Works Alone or in Combination With Cemiplimab for Adult Participants With Metastatic Castration-Resistant Prostate Cancer and Other Tumors
REGN5678, Cemiplimab - Metastatic Castration-Resistant Prostate Cancer (mCRPC), Clear Cell Renal Cell Carcinoma (ccRCC)
Phase 1 / Phase 2RecruitingRegeneron Pharmaceuticals3452019-08-122026-11-04
Intralesional Cemiplimab for Adult Patients With Cutaneous Squamous Cell Carcinoma or Basal Cell Carcinoma
Cemiplimab - Cutaneous Squamous Cell Carcinoma, Basal Cell Carcinoma
Phase 1CompletedRegeneron Pharmaceuticals972019-04-112026-01-21
REGN2810 in Pediatric Patients With Relapsed, Refractory Solid, or Central Nervous System (CNS) Tumors and Safety and Efficacy of REGN2810 in Combination With Radiotherapy in Pediatric Patients With Newly Diagnosed or Recurrent Glioma
cemiplimab (monotherapy), cemiplimab (maintenance), Conventional or hypofractionated - Relapsed Solid Tumor, Refractory Solid Tumor
Phase 1 / Phase 2TerminatedRegeneron Pharmaceuticals572018-09-242025-04-08

Showing 20 of 31. Sign in to see all of them.

Conditions studied

Ovarian Neoplasms (4)  ·  Recurrence (4)  ·  Fallopian Tube Neoplasms (3)  ·  Neoplasm Metastasis (3)  ·  Neoplasms (3)  ·  Carcinoma, Non-Small-Cell Lung (2)  ·  Carcinoma, Renal Cell (2)  ·  Colorectal Neoplasms (2)  ·  Endometrial Neoplasms (2)  ·  Glioblastoma (2)  ·  Glioma (2)  ·  Lymphoma, B-Cell (2)  ·  Lymphoma, Large-Cell, Anaplastic (2)  ·  Lymphoma, T-Cell (2)  ·  Melanoma (2)

Sponsors

Regeneron Pharmaceuticals (20)  ·  Mayo Clinic (2)  ·  National Cancer Institute (NCI) (2)  ·  National Institute of Allergy and Infectious Diseases (NIAID) (2)  ·  Emory University (1)  ·  Inovio Pharmaceuticals (1)  ·  M.D. Anderson Cancer Center (1)  ·  Palleon Pharmaceuticals, Inc. (1)  ·  University of Southern California (1)

Countries

United States (25)  ·  Spain (7)  ·  Netherlands (5)  ·  South Korea (5)  ·  Australia (4)  ·  France (4)  ·  Israel (4)  ·  United Kingdom (4)  ·  Belgium (2)  ·  Brazil (2)  ·  Poland (2)  ·  Austria (1)  ·  Canada (1)  ·  Germany (1)  ·  Greece (1)

Top investigators

Cynthia Gay, MD (1)  ·  Debika Bhattacharya, MD (1)  ·  Gino K In, MD (1)  ·  Jeffrey Skolnik, MD (1)  ·  Jordan Feld, MD, PhD (1)  ·  Joselle Cook, M.B.B.S. (1)  ·  Kah Whye Peng, PhD (1)  ·  Megan Mantica (1)  ·  Michael Lowe, MD (1)  ·  Nora Bennani, M.D. (1)  ·  Nora Bennani, MD (1)  ·  Raymond T. Chung, MD (1)  ·  Timothy A Yap (1)

Results publications

PMID 35175355, PMID 27879972, PMID 29863979, PMID 32554615, PMID 33146741, PMID 33831732, PMID 33929394, PMID 33942954, PMID 36898933, PMID 38449916, PMID 38900987, PMID 39422598, PMID 39652449

NIH funding

2016 (3), 2015 (2), 2019 (2), 2023 (2), P50CA186781 (2), R01CA262613 (2), 2025 (1), P30CA014089 (1), P30CA138292 (1), UM1CA186690 (1), UM1CA186691 (1)